CVE-2023-43770
Published: February 12, 2024
Official Description
Roundcube Webmail contains a persistent cross-site scripting (XSS) vulnerability that can lead to information disclosure via malicious link references in plain/text messages.
CISA KEV Advisory
Roundcube Webmail Persistent Cross-Site Scripting (XSS) Vulnerability
Roundcube Webmail contains a persistent cross-site scripting (XSS) vulnerability that can lead to information disclosure via malicious link references in plain/text messages.
Apply mitigations per vendor instructions or discontinue use of the product if mitigations are unavailable.
Risk Analysis
This vulnerability in Roundcube Webmail allows for persistent cross-site scripting (XSS) through malicious links in plain text messages, potentially leading to information disclosure. With an EPSS score of 0.76431, there is a high likelihood of exploitation, and its presence in CISA's KEV confirms active exploitation, making it an urgent concern.
Active exploitation of this vulnerability has been observed in the wild, as confirmed by its inclusion in CISA's KEV.
Administrators should ensure Roundcube Webmail installations are updated to the latest secure versions to address this XSS vulnerability.
Technical Analysis
CVE-2023-43770 requires local access, meaning attackers must already have a foothold on the target system.
Exploitation requires some privileges, which limits the exposure to scenarios where an attacker has already gained initial access.
CISA has added CVE-2023-43770 to the Known Exploited Vulnerabilities (KEV) catalog, confirming active exploitation in the wild. U.S. federal agencies are required to patch this within the mandated timeframe, and all organizations should treat remediation as urgent.
Exploit & PoC Resources
All References (2)
Quick Facts
Recommended Actions
- →Apply vendor patches immediately
- →Monitor CVE-2023-43770 in threat intel feeds
- →Review IDS/IPS signatures for exploitation attempts
- !CISA KEV: Federal agencies must patch per BOD 22-01 timeline
- !Active exploitation confirmed — treat as P1